# BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

> **NCT06773312** · PHASE1 · RECRUITING · sponsor: **Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Advanced or Metastatic Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** BC001+Sintilimab+XELOX

## Key facts

- **NCT ID:** NCT06773312
- **Lead sponsor:** Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-10
- **Final completion:** 2027-04
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06773312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06773312, "BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06773312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*